Navigation Links
Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
Date:11/27/2008

hlight the exciting compounds that our unique approach to drug discovery and development delivers. This approach, which combines a creative R&D culture and a strong focus on commercialization, has enabled us to successfully progress ZP1846 from discovery through to clinical trials in just four years, creating significant value for our shareholders."

Dr. David Solomon, Chief Executive Officer of Zealand Pharma further commented: "We are delighted to be able to work with Helsinn on the development and commercialization of ZP1846. Helsinn Healthcare has a very strong worldwide presence in the cancer supportive care treatment area where ZP1846 will be a very important product in the prevention and/or treatment of injuries to the intestinal epithelium caused by chemotherapy treatment."

About chemotherapy-induced diarrhea

Chemotherapy-induced diarrhea is a serious debilitating condition affecting patients undergoing treatment with anti-cancer therapies and this gastrointestinal injury may lead to serious complications such as malnutrition, sepsis, dehydration and kidney insufficiency.

There is a strong need for drugs that are able to prevent or treat the mucosal damage and eliminate the diarrhea induced by chemotherapy, and we believe that ZP1846 is useful treatment and/or prevention of an unmet medical need like chemotherapy-induced diarrhea.

About Helsinn Healthcare

Helsinn Healthcare is a privately owned pharmaceutical group with headquarters in Switzerland. Helsinn Healthcare's core business is the licensing of pharmaceuticals in therapeutic areas (oncology, cancer supportive care, pain and inflammation, gastrointestinal). The company's business strategy is to in-license early-stage new chemical entities and to complete their development from the performance of pre-clinical/clinical studies and CMC development to the attainment of market approvals in strategic
'/>"/>

SOURCE Helsinn Healthcare SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
5. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
6. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
7. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... The New York investment bank KTA Capital... agreed an AU$6.7 mil convertible note private pla...vate placement was arranged by KTA Capital as Neur... New York (PRWEB) November 23,...KTA Capital, LLC ("KTA Capital") has ann...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 /PRNe...: DCGN ) today announced that it has received noti...e company,s common stock will be,suspended as of N...ith the,Securities and Exchange Commission, which ...Nasdaq, unless the company files an appeal to the ...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 /PRNe...: DCGN ) today announced the approval of all of it... for the District of Delaware,(the "Bankruptcy Cou...for,relief under Chapter 11 of the United States B... The orders issued by the Bankruptcy Court allow...
(Date:11/24/2009)... SHANGHAI, Nov. 24 /PRNewswire-Asia/ -- Shangh...Drug Administration (SFDA) has approved the,invest...insulin project,(Nodlin), an innovative insulin fo...ows Biolaxy to initiate its first phase I clinical...ristic of high blood glucose and poor,metabolism. ...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2
... , Shareholders are Urged to Vote their YELLOW ...d and Independent Directors to the Biovail Board, ...Shareholders of Biovail today said that Biovail Co...lead its shareholders by making the focal point of...mply about governance reform and has already been ...
... Results from Phase 2 Clinical Trials of Carfilzom...anced Solid Tumors Featured in Oral Presentations ...today announced that data from clinical trials of ... tumors will be presented at the 2009 Annual Meeti...SCO) being held May 29 - June 2, 2009 in Orlando, ...
... LA JOLLA, Calif., May 15 Fate Therapeutics, In...e intellectual property rights jointly owned by Ch... Hospital. This intellectual property covers comp...stem cells. These proprietary technologies develo...l Program at Children,s Hospital Boston and a scie...
Other Biology Technology:The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 2The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 3The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 4The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 5The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 6The Concerned Shareholders of Biovail Say Biovail Has Misled Shareholders 7Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 2Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting 3Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 2Fate Therapeutics Granted Exclusive License for Stem Cell Modulators by Children's Hospital Boston and Massachusetts General Hospital 3
(Date:11/25/2009)... Sarit Larisch, Head of the Cell Death Research La...f Biology, has been awarded the prestigious Johnso... exploring the cause of brain cell damage in Parki...ear to scientists in support of innovation and exc...icially conferred earlier this month at an event a...
(Date:11/24/2009)...housands of years it has been prescribed by tradit...ts from headaches and stomach pain to fever and fl...stle University have been able to scientifically p...ata otherwise known as Brazilian mint. , Testin...am led by researcher Graciela Rocha was able to sh...
(Date:11/24/2009)...tomic-level action of a remarkable class of ring-s...hers with the Lawrence Berkeley National Laborator...crystallography beamline at the Advanced Light Sou... in gene expression and replication, and are vital...as infectious agents, such as the human papillomav...
Breaking Biology News(10 mins):Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Got a pain? -- Have a cup of Brazilian mint 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4A Safety Slip 3A Dont Hold a Child in Your Lap on Playground Slides 56173 1A Safety Slip 3A Dont Hold a Child in Your Lap on Playground Slides 56173 2Americas No 1 Pharmacy Names Great Health as Its Exclusive Health and Wellness Magazine 56168 1Rodgers Introduces SamarionSolution to International Audience 56164 1Rodgers Introduces SamarionSolution to International Audience 56164 2
...ational group of researchers today unveiled a deta...or histocompatibility complex (MHC), the most impo...n response to infection, autoimmune disease and or...ne in the analysis of genetic variability for this... foundation for future efforts aimed at uncovering...
...,s most widely used organic insecticide, a plucky ...r short, requires the assistance of other microbes...as found. , Writing in the Sept. 26 issue of the ...NAS), a team of researchers from the University of...f the native bacteria that colonize the insect gut...
...rs have achieved an effective immune response to a...-quarter of the norm when they added a chemical mi...the November 1 issue of Clinical Infectious Diseas...--a substance that increases the immune system,s a..., the investigators used inactivated H9N2 influenz...
Other Biology News:International team analyzes human genetic variation in key immune region 2International team analyzes human genetic variation in key immune region 3Most widely used organic pesticide requires help to kill 2Most widely used organic pesticide requires help to kill 3
Adaptor Hind III - Sma I from Takara Mirus Bio
DryStrip aligners from GE Healthcare, formerly Amersham Biosciences
Normal Calf Serum from Equitech-Bio
... at the 3, 3', 4, and 4' positions. It is intended...ation of PGE1 by GC- or LC-mass spectrometry. PGE1...ihomo-γ-linolenic acid (DGLA), but it is vi...s or other animals. Its pharmacology includes vaso...
Biology Products: